Nanoparticles and radiotracers: advances toward radionanomedicine

Pratt, Edwin C.; Shaffer, Travis M.; Grimm, Jan

doi:10.1002/wnan.1402

Cited by 54 publications

(51 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In SPECT, each radionuclide decays which is detected by a gamma camera (single or multihead). Radionuclides either can be directly labeled ( 11 C, 18 F, 76 Br and 124 I) or can be chelated ( 64 Cu, 68 Ga, 89 Zr, 90 Y, 99m Tc, and 177 Lu) onto a wide variety of NP . Matching the half‐life of the radionuclide with the pharmacokinetics of clearance of the probe can reduce exposure to the living subject.…”

Section: Cellular Prelabeling and Cell Imaging With Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Engineering molecular imaging strategies for regenerative medicine

Willadsen

Chaise

Yarovoy

et al. 2018

Bioengineering & Transla Med

View full text Add to dashboard Cite

The reshaping of the world's aging population has created an urgent need for therapies for chronic diseases. Regenerative medicine offers a ray of hope, and its complex solutions include material, cellular, or tissue systems. We review basics of regenerative medicine/stem cells and describe how the field of molecular imaging, which is based on quantitative, noninvasive, imaging of biological events in living subjects, can be applied to regenerative medicine in order to interrogate tissues in innovative, informative, and personalized ways. We consider aspects of regenerative medicine for which molecular imaging will benefit. Next, genetic and nanoparticle‐based cell imaging strategies are discussed in detail, with modalities like magnetic resonance imaging, optical imaging (near infra‐red, bioluminescence), raman microscopy, and photoacoustic microscopy), ultrasound, computed tomography, single‐photon computed tomography, and positron emission tomography. We conclude with a discussion of “next generation” molecular imaging strategies, including imaging host tissues prior to cell/tissue transplantation.

show abstract

Section: Cellular Prelabeling and Cell Imaging With Nanoparticlesmentioning

confidence: 99%

“…Radionuclides either can be directly labeled ( 11 C, 18 F, 76 Br and 124 I) or can be chelated ( 64 Cu, 68 Ga, 89 Zr, 90 Y, 99m Tc, and 177 Lu) onto a wide variety of NP. 131 imaged. This is possible because the surface can be treated for chelation of radionuclides associated with imaging.…”

Section: Single-photon Emission Computed Tomography Cell Imaging Wimentioning

confidence: 99%

Engineering molecular imaging strategies for regenerative medicine

Willadsen

Chaise

Yarovoy

et al. 2018

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…[13-14] using radioactive nuclides conjugated to small molecules (e.g. 18 F-fluorodeoxyglucose ( 18 F-FDG)) or antibodies.…”

Section: Imagingmentioning

confidence: 99%

Molecular Imaging in Nanotechnology and Theranostics

et al. 2017

View full text Add to dashboard Cite

The “Molecular Imaging in Nanotechnology and Theranostics” (MINT) Interest Group of the World Molecular Imaging Society (WMIS) was founded in 2015 and was officially inaugurated during the 2016 World Molecular Imaging Conference (WMIC). The MINT interest group was created in response to the exponential growth of the fields of Nanotechnology and Theranostics in recent years, and the resulting need to provide a more organized and focused forum on these topics at the WMIS and the WMIC. The overarching goal of MINT is to bring together the many scientists who work on molecular imaging approaches using nanotechnology, and those that work on theranostic agents. MINT therefore represents scientists, labs, and institutes that are very diverse in their scientific backgrounds and areas of expertise, reflecting the wide array of materials and approaches that drive these fields. In this short review, we attempt to provide a condensed overview over some of the key areas covered by MINT. Given the breadth of the fields and the given space constraints, we have limited the coverage to the realm of nano-constructs, although theranostics is certainly not limited to this domain. We will also focus only on the most recent developments of the last 3-5 years, in order to provide the reader with an intuition of what is “in the pipeline” and has potential for clinical translation in the near future.

show abstract

“…In biomedical imaging, NPs can provide or enhance the distinction of normal from diseased tissue, whether that be tumor margins for image guided surgery, sentinel lymph node (SLN) drainage in metastatic cancer, or even identifying sites of inflammation [70]. In this context, radiolabeled nanoparticles as theranostic agents have been widely used and summarized in recent review articles [71–75].…”

Section: New Radiolabeled Probes For Monitoring Cancer Therapymentioning

confidence: 99%

The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

Fernandes

Ferreira

Soares

et al. 2017

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Despite recent advances in the development of new therapeutic agents and diagnostic imaging modalities, cancer is still one of the main causes of death worldwide. A better understanding of the molecular signature of cancer has promoted the development of a new generation of anti-cancer drugs and diagnostic agents that specifically target molecular components such as genes, ligands, receptors and signaling pathways. However, intrinsic heterogeneity of tumors has hampered the overall success of target therapies even among patients with similar tumor types but unpredictable different responses to therapy. In this sense, post-treatment response monitoring becomes indispensable and nuclear medicine imaging modalities could provide the tools for an early indication of therapeutic efficacy. Herein, we briefly discuss the current role of PET and SPECT imaging in monitoring cancer therapy together with an update on the current radiolabeled probes that are currently investigated for tumor therapy response assessment.

show abstract

Nanoparticles and radiotracers: advances toward radionanomedicine

Cited by 54 publications

References 103 publications

Engineering molecular imaging strategies for regenerative medicine

Engineering molecular imaging strategies for regenerative medicine

Molecular Imaging in Nanotechnology and Theranostics

The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

Contact Info

Product

Resources

About